Indication
Afibrinogenemia
Afibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood. Read more about Afibrinogenemia
4 drugs 4 manufacturers
Drugs that treat it
Common Afibrinogenemia therapies.
FIBRYGA (fibrinogen)
RIASTAP (fibrinogen)
FESILTY (fibrinogen, human-chmt)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAfibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood.
Typically inherited in an autosomal recessive pattern due to mutations in the fibrinogen gene cluster (*FGA*, *FGB*, or *FGG*), it can also rarely be acquired secondary to severe hepatic failure or hyperconsumptive states.
Pathophysiologically, the absence of fibrinogen impairs both stable fibrin clot formation and normal platelet aggregation, disrupting primary and secondary hemostasis.
Clinically, affected individuals experience a lifelong bleeding diathesis that frequently presents in the neonatal period with prolonged umbilical cord hemorrhage, followed by mucosal bleeding, hemarthroses, hematomas, and potentially fatal spontaneous intracranial hemorrhage, paradoxical thromboembolism, or recurrent early pregnancy loss.
- nih.gov
Afibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood Typically inherited in an autosomal recessive pattern due to mutations in the fibrinogen gene cluster (*FGA*, *FGB*, or *FGG*), it can also rarely be acquired secondary to severe hepatic failure or hyperconsumptive states Pathophysiologically, the absence of fibrinogen impairs both stable fibrin clot formation and normal...
- rarediseases.org
Afibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood Clinically, affected individuals experience a lifelong bleeding diathesis that frequently presents in the neonatal period with prolonged umbilical cord hemorrhage, followed by mucosal bleeding, hemarthroses, hematomas, and potentially fatal spontaneous intracranial hemorrhage, paradoxical thromboembolism, or recurrent ea...
- medlineplus.gov
Typically inherited in an autosomal recessive pattern due to mutations in the fibrinogen gene cluster (*FGA*, *FGB*, or *FGG*), it can also rarely be acquired secondary to severe hepatic failure or hyperconsumptive states
- nih.gov
Clinically, affected individuals experience a lifelong bleeding diathesis that frequently presents in the neonatal period with prolonged umbilical cord hemorrhage, followed by mucosal bleeding, hemarthroses, hematomas, and potentially fatal spontaneous intracranial hemorrhage, paradoxical thromboembolism, or recurrent early pregnancy loss
Personalize your experience
Follow Afibrinogenemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.